Advertisement

Pharmacokinetic Study of Cytosine Arabinoside in Patients with Acute Myelogeneous Leukemia

  • P. Preusser
  • H. J. Pielken
  • H.-J. Bauch
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)

Abstract

The aim of the study was to evaluate the pharmacokinetics of cytosine arabinoside (Ara-C) and its extracellular metabolite uracil arabinoside Ara-U in patients with acute myelogeneous leukemia (AML) in correlation to response in therapy. There are few data [4] that indicate that high and long-lasting Ara-U plasma levels increase the incorportion of Ara-C into DNA and decrease the catabolism of Ara-C, and might also play a role in getting a response in therapy. We therefore investigated the pharmacokinetics of Ara-C and Ara-U in plasma of 17 patients with AML.

Keywords

Acute Myelogeneous Leukemia Kinetic Curf Cytosine Arabinoside Area Under Curve Uracil Arabinoside 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bender RA, Zwelling LA, Doroshow JH, Locker GY, Hande KR, Murinson DS, Cohen M, Meyers CE, Chabner A (1978) Antineoplastic drugs: clinical pharmacology and therapeutic use. Drugs 16: 46–51PubMedCrossRefGoogle Scholar
  2. 2.
    Breithaupt H, Schick J (1981) Determination of cytarabine and uracil arabinoside in human plasma and cerebrospinal fluid by high-performance liquid chromatography. J Chromatogr 225: 99–106PubMedCrossRefGoogle Scholar
  3. 3.
    Bury RW, Keary PJ (1978) Determination of cytosine arabinoside in human plasma by high-pressure liquid chromatography. J Chromatogr 146: 350–359PubMedCrossRefGoogle Scholar
  4. 4.
    Capizzi RL, Yang JL, Cheng E, Cheng JC (1983) Pre-clinical and clinical pharmacology of high-dose Ara-C (HiDAC): aspects of “self potentiation” accounting for its unique therapeutic utility. In: 13th Int. Congress of Chemotherapy. Proceedings, Pt 216, pp 13–19Google Scholar
  5. 5.
    lacoboni S, Plunkett W, Keating M, McCredie K, Freireich E (1985) Pharmacologic direction of continuous infusion high dose Ara-C (CIHDAC) for refractory acute leukemia (RAL) and chronic myelogeneous leukemia blast crisis (CML-BC). American Society of Clinical Oncology 4:173, ASCO Abstr 674Google Scholar
  6. 6.
    Kato Y, Seita T, Hashimoto T, Shimuzu A (1977) Separation of nucleic acid bases and nucleosides by high-performance affinity chromatography. J Chromatogr 134: 204–214PubMedCrossRefGoogle Scholar
  7. 7.
    Montgomery JA, Johnston TP, Thomas Hi, Piper JR, Temple Jr C (1979) The use of microparticular reversed-phase packing in high-pressure liquid chromatography of compounds of biological interest. Advan Chromatogr 15: 169–178Google Scholar
  8. 8.
    Pallavicini MG, Mazrimas JA (1980) High-performance liquid chromatographic analysis of cytosine arabinoside and metabolites in biological samples. J Chromatogr 183: 449–458PubMedCrossRefGoogle Scholar
  9. 9.
    Plunkett W., Liliemark JO (1985) Evidence that accumulation of Ara-CTP by leukemic cells is saturated during high-dose Ara-C infusion: suggestions for increased efficiency of drug administration. American Society of Clinical Oncology 4:50, ASCO Abstr 192Google Scholar
  10. 10.
    Van Prooijen HC, Vierwinden G, van Ehmond J, Wessels JMC, Haanen C (1976) A sensitive bio-assay for pharmacokinetic studies of cytosine arabinoside in man. Europ J Cancer 12: 889–893CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • P. Preusser
    • 1
  • H. J. Pielken
    • 1
  • H.-J. Bauch
    • 2
  1. 1.Departments of Internal MedicineUniversity of Münster ClinicMünsterFederal Republic of Germany
  2. 2.Arteriosclerosis Research InstituteUniversity of MünsterGermany

Personalised recommendations